

Message

---

**From:** MARVIN, THOMAS [AG/1920] [thomas.marvin@monsanto.com]  
**Sent:** 2/14/2017 11:22:21 PM  
**To:** Keigwin, Richard [Keigwin.Richard@epa.gov]  
**Subject:** Tioxazafen New Active Ingredient, FR Notice?

Greetings Rick,

First, congratulations on your appointment as Acting Office Director. I look forward to working with you in the capacity of my new role—leading the regulatory team at Monsanto’s DC office. Second, I am requesting your assistance to understand the status of our new active ingredient nematicide, Tioxazafen, that is pending EPA’s publication in the FR and the start of a public comment period. We understood that EPA was prepared to initiate that action in early January, 2017, but that the “Regulatory Freeze” caused a delay. As each day passes, our commercial timelines are increasingly jeopardized. We are desperately looking for some indication of the current status and timing of EPA’s FR publication. Please let me know if there is anything we can do to help explain the urgency, and thank you in advance for any information you can provide.

Tom

Tom Marvin  
Director, Federal Regulatory Affairs  
Monsanto Co.  
1300 I Street, NW  
Washington, DC 20005  
Cell: 314-308-6836  
Desk: 314-694-7901

This email and any attachments were sent from a Monsanto email account and may contain confidential and/or privileged information. If you are not the intended recipient, please contact the sender and delete this email and any attachments immediately. Any unauthorized use, including disclosing, printing, storing, copying or distributing this email, is prohibited. All emails and attachments sent to or from Monsanto email accounts may be subject to monitoring, reading, and archiving by Monsanto, including its affiliates and subsidiaries, as permitted by applicable law. Thank you.